United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies
- PMID: 23972982
- PMCID: PMC3761410
- DOI: 10.1016/j.currproblcancer.2013.06.001
United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies
References
-
- Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298(5600):1912–34. Epub 2002/12/10. - PubMed
-
- Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 2002;3(6):561–97. Epub 2002/10/09. - PubMed
-
- FDA/Center for Drug Evaluation Research. Label information for Gleevec [homepage on the Internet] Silver Spring, MD: Food and Drug Administration; 2003. [updated 2003 Apr 18; cited 2013 Feb 11] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf.
-
- FDA/Center for Drug Evaluation Research. Label information for Bosulif [homepage on the Internet] Silver Spring, MD: Food and Drug Administration; 2012. [updated 2012 Sep 4; cited 2013 Feb 11] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
